Cargando…
Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828519/ https://www.ncbi.nlm.nih.gov/pubmed/35242383 http://dx.doi.org/10.21037/jtd-21-1700 |
| _version_ | 1784647864779014144 |
|---|---|
| author | Iwamoto, Natsuhiko Kim, Young Hak Iwatsubo, Shigeaki Nishimura, Yoshihiro Funada, Yasuhiro |
| author_facet | Iwamoto, Natsuhiko Kim, Young Hak Iwatsubo, Shigeaki Nishimura, Yoshihiro Funada, Yasuhiro |
| author_sort | Iwamoto, Natsuhiko |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8828519 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88285192022-03-02 Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation? Iwamoto, Natsuhiko Kim, Young Hak Iwatsubo, Shigeaki Nishimura, Yoshihiro Funada, Yasuhiro J Thorac Dis Letter to the Editor AME Publishing Company 2022-01 /pmc/articles/PMC8828519/ /pubmed/35242383 http://dx.doi.org/10.21037/jtd-21-1700 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Letter to the Editor Iwamoto, Natsuhiko Kim, Young Hak Iwatsubo, Shigeaki Nishimura, Yoshihiro Funada, Yasuhiro Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation? |
| title | Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation? |
| title_full | Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation? |
| title_fullStr | Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation? |
| title_full_unstemmed | Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation? |
| title_short | Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation? |
| title_sort | is there a role for sequential afatinib and osimertinib in patients with egfr mutation? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828519/ https://www.ncbi.nlm.nih.gov/pubmed/35242383 http://dx.doi.org/10.21037/jtd-21-1700 |
| work_keys_str_mv | AT iwamotonatsuhiko istherearoleforsequentialafatinibandosimertinibinpatientswithegfrmutation AT kimyounghak istherearoleforsequentialafatinibandosimertinibinpatientswithegfrmutation AT iwatsuboshigeaki istherearoleforsequentialafatinibandosimertinibinpatientswithegfrmutation AT nishimurayoshihiro istherearoleforsequentialafatinibandosimertinibinpatientswithegfrmutation AT funadayasuhiro istherearoleforsequentialafatinibandosimertinibinpatientswithegfrmutation |